Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

@article{Kaatz2012GuidanceOT,
  title={Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors},
  author={Scott Kaatz and Peter A Kouides and David A. Garcia and Alex C Spyropolous and Mark Andrew Crowther and James D Douketis and Anthony K Chan and Andra H. James and Stephan Moll and Thomas L. Ortel and Elizabeth M Van Cott and Jack Ansell},
  journal={American Journal of Hematology},
  year={2012},
  volume={87}
}
The new oral anticoagulants dabigatran, rivaroxaban and apixaban have advantages over warfarin which include no need for laboratory monitoring, less drug–drug interactions and less food‐drug interactions. However, there is no established antidote for patients who are bleeding or require emergent surgery and there is a paucity of evidence to guide the clinical care during these situations. Members of thrombosis and anticoagulation groups participating in the Thrombosis and Hemostasis Summit of… Expand
Reversal of Novel Anticoagulants: Role of Clotting Factors and Complex Concentrates
TLDR
The purpose of this review is to discuss the current available data and management considerations and ultimately aid the clinician in the use of clotting factors and complex concentrates in the setting of a pathologic bleeding event. Expand
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
TLDR
The pharmacology and effectiveness of the oral activated factor X inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran are reviewed. Expand
Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants.
TLDR
The indications and pharmacokinetics of available DOACs are described and the role of specific reversal agents, such as the recently approved idarucizumab for reversal of the direct thrombin inhibitor dabigatran are discussed. Expand
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
TLDR
Clinical studies are needed to determine the best method for reversal of the novel oral anticoagulation agents when bleeding occurs, and Hemodialysis is a therapeutic option for dabigatran-related bleeding. Expand
Emergency department management of patients on novel oral anticoagulant agents.
TLDR
The evidence on the use and risks of enriched clotting factor preparations as well as the clinical and laboratory evaluation that will guide their management are examined. Expand
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects
Purpose of reviewWarfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emergedExpand
Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors.
  • J. Augoustides
  • Medicine
  • Journal of cardiothoracic and vascular anesthesia
  • 2012
TLDR
The oral direct factor Xa inhibitors include rivaroxaban and apixaban that recently have been evaluated comprehensively in multiple randomized clinical trials and ushered in a new paradigm for clinical anticoagulation, with edoxaban already in phase III clinical trials. Expand
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
TLDR
Preclinical data suggest that prothrombin complex concentrates (PCCs) may have potential in this setting, and use of PCCs may be considered a reasonable approach in dire clinical situations; however, a consensus has not yet been reached regarding PCC use or dosing, due to lack of clinical data. Expand
The pharmacology of novel oral anticoagulants
TLDR
The pharmacokinetic process of oral medication use is reviewed, the newer anticoagulants, their pharmacology, individual pharmacokinetics features, and possible explanations for the differences in bleeding outcomes observed in the clinical trials are explored. Expand
Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
TLDR
Management of the newer direct oral anticoagulant agents requires careful adherence to primary measures of bleeding care, knowledge of their mechanism of action, and familiarity with the unapproved and untested reversal strategies that may be required in patients with life-threatening bleeding. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
TLDR
This work focuses on the management of bleeding in anticoagulated patients, with particular regard to novel antICOagulants, and a lack of a widely available antidote is focused on. Expand
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
TLDR
Members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with about new oral anticoagulant drugs. Expand
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
TLDR
Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticonvulsant action of dabigatran at the PCC dose used in this study. Expand
The use of dabigatran in elderly patients.
TLDR
2 clinical cases are reported, including 1 fatal case, illustrating the concern regarding the risk of bleeding events in elderly patients of dabigatran etexilate. Expand
Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates
Rivaroxaban is an oral, direct Factor Xa (FXa) inhibitor that has been recommended for approval by the Committee for Medicinal Products for Human Use for the prevention of venous thromboembolismExpand
The Successful Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat Tail Bleeding Model Do Not Correlate with Ex Vivo Markers of Anticoagulation
TLDR
This study illustrates that high doses of dabigtran that induce bleeding can be reversed by coagulation factor concentrates at clinically recommended doses in this animal model, however, the systemic coagulated parameters routinely measured clinically do not predict this reversal. Expand
New antithrombotics: the impact on global health care.
TLDR
Clinicians should be vigilant concerning these agents and be prepared to inform patients and make decisions with their use. Expand
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.
TLDR
There is a low but quantifiable risk of thromboembolism in VKA-treated patients receiving PCCs for anticoagulation reversal, and these findings should be confirmed in randomised, controlled trials. Expand
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
TLDR
The analysis provides a thorough PK characterization of dabigatran in the AF patient population from RE‐LY and none of the covariates investigated, with the exception of renal function, warrants dose adjustment. Expand
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
TLDR
The rationale for development of new antithrombotic agents is outlined, the new antiplatelet, anticoagulant, and fibrinolytic drugs are described, and clinical perspectives on the opportunities and challenges faced by these novel agents are provided. Expand
...
1
2
3
4
5
...